Categories: NewsPharmaceutical

PharmaCord Announces Leadership Expansion, Appointing Rob Brown to Chief Growth Officer

JEFFERSONVILLE, IN / ACCESSWIRE / April 17, 2024 / PharmaCord LLC, a leading provider of patient support services for the pharmaceutical industry, is pleased to announce the appointment of Rob Brown as Chief Growth Officer. Brown, who has been a part of the PharmaCord team since June 2021 and served as the Vice President of Strategic Accounts, will now oversee the business development and marketing teams, driving strategic initiatives to accelerate PharmaCord’s growth trajectory. As Chief Growth Officer, Brown will develop and execute targeted business development initiatives, deliver innovative solutions, and further solidify PharmaCord’s position as the preferred patient services partner.

Rob Brown, Chief Growth Officer, PharmaCord

“Rob has been a driving force behind PharmaCord’s success, demonstrating exceptional leadership and vision since joining our team,” said Nitin Sahney, founder and CEO of PharmaCord. “His strategic acumen, understanding of the client and proven track record uniquely position him to lead our expansion efforts within the industry.”

This appointment is part of PharmaCord’s broader investment plan into sales and marketing functions, reflecting a commitment to sustained growth and client-centric excellence.

Brown has over 20 years of experience driving strategic initiatives and supporting the distribution and commercialization design and operations for pharmaceutical and biotech partners. He has successfully delivered operational excellence and market share growth for industry frontrunners such as McKesson, CVS, Omnicare and Cardinal Health. Prior to joining PharmaCord, Brown served as Vice President & General Manager for McKesson’s pharmacy services where he had accountability for Biologics specialty pharmacy and RxCrossroads program pharmacy operations. Prior to that, he had direct operational and business development oversight for the commercialization services business of Omnicare Specialty Care Group comprised of RxCrossroads and Advanced Care Scripts.

Brown has a Bachelor of Arts in English from The College of William and Mary.

About PharmaCord

As a patient services provider, PharmaCord works on behalf of drug manufacturers to simplify the patient therapeutic journey. Through a combination of its proprietary PharmaCord Lynk™ technology suite, exceptionally talented team members and its non-commercial pharmacy PharmaCord Scripts™, PharmaCord helps patients enhance their experience accessing and adhering to their critical medications. To learn more about how PharmaCord improves commercial outcomes for life sciences companies, visit pharmacord.com.

Contact Information

Paige Hobbs
Associate Director of Marketing
phobbs@pharmacord.com

SOURCE: PharmaCord

View the original press release on newswire.com.

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

1 hour ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

1 hour ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

1 hour ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

1 hour ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

1 hour ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

4 hours ago